SCHEMBL3873167

SCHEMBL3873167

CC(=O)Nc1ccc(S(=O)(=O)Nc2ccc3[nH]c4c(c3c2)CCN(C)C4)cc1

nearest known ligand 0.63

Predicted protein targets (top 15)

geneUniProtsupporting neighboursconfidence
MAPT P10636 12/20 0.63
HTR6 P50406 3/20 0.55
HTR1A P08908 2/20 0.55
HTR2C P28335 2/20 0.55
HTR7 P34969 2/20 0.55
MEN1 O00255 1/20 0.53
RAB9A P51151 1/20 0.53
KMT2A Q03164 1/20 0.53
TP53 P04637 8/20 0.51
LMNA P02545 4/20 0.48
PKM P14618 2/20 0.48
THRB P10828 2/20 0.48
ALDH1A1 P00352 1/20 0.47
GAA P10253 1/20 0.47
POLB P06746 1/20 0.46

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL3874868 0.87 HTR6 (0.57) MAPTHTR6HTR1AHTR2CHTR7
SCHEMBL4022862 0.82 HTR6 (0.59) MAPTHTR6HTR1AHTR2CHTR7
SCHEMBL12316100 0.82 HTR2C (0.56) MAPTHTR6HTR1AHTR2CHTR7
Hydrochloric Acid SCHEMBL4031202 0.82 HTR6 (0.60) MAPTHTR6HTR1AHTR2CHTR7
SCHEMBL3874883 0.81 RORA (0.47) MAPTHTR6HTR1AHTR2CHTR7
SCHEMBL12316095 0.81 HTR2C (0.55) MAPTHTR6HTR1AHTR2CHTR7
SCHEMBL12316067 0.79 HTR6 (0.57) MAPTHTR6HTR1AHTR2CHTR7
SCHEMBL4024729 0.77 HTR6 (0.56) HTR6HTR1AHTR2CHTR7
SCHEMBL12316089 0.75 HTR6 (0.53) MAPTHTR6HTR1AHTR2CHTR7
SCHEMBL3877938 0.74 KDM4E (0.50) MAPTHTR6HTR1AHTR2CHTR7

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 19 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8263609-B2 Tetrahydro-β-carbolin-sulfonamide derivatives as 5-Ht6 ligands LABORATORIOS DEL DR. ESTEVE, S.A. (ES) 2012-09-11 US claimed
US-20090264457-A1 Combination of at least two 5HT6-Ligands LABORATORIOS DEL DR. ESTEVE, S.A. (ES) 2009-10-22 US claimed
EP-1919475-B1 TETRAHYDRO- BETA-CARBOLIN-SULFONAMIDE DERIVATIVES AS 5-HT6 LIGANDS ESTEVE LABOR DR (ES) 2009-03-11 EP claimed
EP-2020230-A1 Combination of at least two 5-HT6-Ligands Laboratorios del Dr. Esteve S.A. (ES) 2009-02-04 EP claimed
US-20080280942-A1 Tetrahydro-Beta-Carbolin-Sulfonamide Derivatives as 5-Ht6 Ligands LABORATORIES DEL DR. ESTEVE, S.A. (ES) 2008-11-13 US claimed
EP-1747779-A1 Tetrahydro-b-carbolin-sulfonamide derivatives as 5-HT6 ligands LABORATORIOS DEL DR. ESTEVE, S.A. (ES) 2007-01-31 EP claimed
US-8263609-B2 Tetrahydro-β-carbolin-sulfonamide derivatives as 5-Ht6 ligands LABORATORIOS DEL DR. ESTEVE, S.A. (ES) 2012-09-11 US disclosed
US-8263609-B2 Tetrahydro-β-carbolin-sulfonamide derivatives as 5-Ht6 ligands LABORATORIOS DEL DR. ESTEVE, S.A. (ES) 2012-09-11 US disclosed
US-8263609-B2 Tetrahydro-β-carbolin-sulfonamide derivatives as 5-Ht6 ligands LABORATORIOS DEL DR. ESTEVE, S.A. (ES) 2012-09-11 US disclosed
US-20090264457-A1 Combination of at least two 5HT6-Ligands LABORATORIOS DEL DR. ESTEVE, S.A. (ES) 2009-10-22 US disclosed
EP-1919475-B1 TETRAHYDRO- BETA-CARBOLIN-SULFONAMIDE DERIVATIVES AS 5-HT6 LIGANDS ESTEVE LABOR DR (ES) 2009-03-11 EP disclosed
EP-1919475-B1 TETRAHYDRO- BETA-CARBOLIN-SULFONAMIDE DERIVATIVES AS 5-HT6 LIGANDS ESTEVE LABOR DR (ES) 2009-03-11 EP disclosed
EP-2020230-A1 Combination of at least two 5-HT6-Ligands Laboratorios del Dr. Esteve S.A. (ES) 2009-02-04 EP disclosed
US-20080280942-A1 Tetrahydro-Beta-Carbolin-Sulfonamide Derivatives as 5-Ht6 Ligands LABORATORIES DEL DR. ESTEVE, S.A. (ES) 2008-11-13 US disclosed
US-20080280942-A1 Tetrahydro-Beta-Carbolin-Sulfonamide Derivatives as 5-Ht6 Ligands LABORATORIES DEL DR. ESTEVE, S.A. (ES) 2008-11-13 US disclosed
US-20080280942-A1 Tetrahydro-Beta-Carbolin-Sulfonamide Derivatives as 5-Ht6 Ligands LABORATORIES DEL DR. ESTEVE, S.A. (ES) 2008-11-13 US disclosed
WO-2007028460-A1 TETRAHYDRO-β-CARBOLIN-SULFONAMIDE DERIVATIVES AS 5-HT6 LIGANDS LABORATORIOS DEL DR. ESTEVE, S.A. (ES) 2007-03-15 WO disclosed
EP-1747779-A1 Tetrahydro-b-carbolin-sulfonamide derivatives as 5-HT6 ligands LABORATORIOS DEL DR. ESTEVE, S.A. (ES) 2007-01-31 EP disclosed
EP-1747779-A1 Tetrahydro-b-carbolin-sulfonamide derivatives as 5-HT6 ligands LABORATORIOS DEL DR. ESTEVE, S.A. (ES) 2007-01-31 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20090264457-A1 Combination of at least two 5HT6-Ligands HTR6, HTR3B, HTR4 MAPT 468/4885HTR6 1/4885HTR1A 8/4885
US-20080280942-A1 Tetrahydro-Beta-Carbolin-Sulfonamide Derivatives as 5-Ht6 Ligands HTR6, HTR5A, HTR1B MAPT 2845/4885HTR6 1/4885HTR1A 9/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.